Patients Derived Organoids as a Promising Tool to Tailor Ovarian Cancer Therapies (PANDORA).

Launched by CENTRO DI RIFERIMENTO ONCOLOGICO - AVIANO · Jan 19, 2024

Keywords

ClinConnect Summary

The PANDORA clinical trial is studying how to better tailor treatments for women with ovarian cancer. Researchers want to find out if using small, patient-derived organoids—tiny models made from a patient’s tumor—can help predict how well different treatments will work for each individual. By testing these organoids with various drugs, they hope to learn more about which therapies might be most effective for real patients in the clinic.

To participate in this study, women must be at least 18 years old and have a diagnosis of ovarian cancer. They will need to provide a tumor sample or fluid from the abdomen, which will be used for research purposes. Participants can expect to be closely monitored and have the opportunity to contribute to important research that might improve future treatments for ovarian cancer. It’s important to note that women who are pregnant, breastfeeding, or have had certain other cancers in the past five years may not be eligible for this trial.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Signed informed consent form;
• • 2. Female sex;
• • 3. Age ≥18 years;
• • 4. Diagnosis of ovarian cancer;
• • 5. Availability of tumor sample or ascites that is planned to be stored in the Institutional Biobank for research purpose
• Exclusion Criteria:
• • 1. Patients for which the tumor/ascites biobanking process could compromise the diagnostic assessments;
• • 2. Pregnancy or breast-feeding
• • 3. History of concomitant or previous malignancy in the last 5 years